IL185182A0 - Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors - Google Patents
Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumorsInfo
- Publication number
- IL185182A0 IL185182A0 IL185182A IL18518207A IL185182A0 IL 185182 A0 IL185182 A0 IL 185182A0 IL 185182 A IL185182 A IL 185182A IL 18518207 A IL18518207 A IL 18518207A IL 185182 A0 IL185182 A0 IL 185182A0
- Authority
- IL
- Israel
- Prior art keywords
- defibrotide
- oligodeoxyribonucleotides
- dependent tumors
- treating angiogenesis
- angiogenesis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 title 1
- 229960004120 defibrotide Drugs 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000336A ITMI20050336A1 (it) | 2005-03-03 | 2005-03-03 | Formulazione ad attivita' anti-tumorale |
| US73140405P | 2005-10-28 | 2005-10-28 | |
| PCT/EP2006/060304 WO2006094916A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL185182A0 true IL185182A0 (en) | 2008-01-20 |
Family
ID=36572331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL185182A IL185182A0 (en) | 2005-03-03 | 2007-08-09 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| IL185181A IL185181A0 (en) | 2005-03-03 | 2007-08-09 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| IL185258A IL185258A (en) | 2005-03-03 | 2007-08-14 | Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL185181A IL185181A0 (en) | 2005-03-03 | 2007-08-09 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
| IL185258A IL185258A (en) | 2005-03-03 | 2007-08-14 | Oligodeoxyribonucleotides for use in the treatment of angiogenesis-dependent tumors in human |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080194506A1 (enExample) |
| EP (2) | EP1853277A1 (enExample) |
| JP (2) | JP2008531647A (enExample) |
| KR (3) | KR20070121001A (enExample) |
| AU (2) | AU2006222044A1 (enExample) |
| CA (2) | CA2598613A1 (enExample) |
| IL (3) | IL185182A0 (enExample) |
| MX (2) | MX2007010754A (enExample) |
| WO (2) | WO2006094917A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031714A1 (it) | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| US8187897B2 (en) | 2008-08-19 | 2012-05-29 | International Business Machines Corporation | Fabricating product chips and die with a feature pattern that contains information relating to the product chip |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| CN110079580B (zh) | 2012-06-22 | 2022-12-06 | 真蒂奥姆责任有限公司 | 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| SG11202000952PA (en) | 2017-08-03 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Formulations comprising a nucleic acid in a high concentration |
| MX2020010689A (es) | 2018-04-12 | 2021-01-20 | Jazz Pharmaceuticals Inc | Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion. |
| US20220023533A1 (en) | 2018-12-07 | 2022-01-27 | Jazz Phrmaceticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| US20230190783A1 (en) | 2020-02-28 | 2023-06-22 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) * | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| IT1252174B (it) * | 1991-12-09 | 1995-06-05 | Crinos Industria Farmaco | Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| AU754242B2 (en) * | 1997-04-28 | 2002-11-07 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| JP2002512508A (ja) * | 1997-05-30 | 2002-04-23 | マクギル・ユニヴァーシティ | Dnaメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド |
| DE19740384A1 (de) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN |
| US7514414B2 (en) * | 2001-09-24 | 2009-04-07 | The United States Of America As Represented By The Department Of Health And Human Services | Suppressors of CpG oligonucleotides and methods of use |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
-
2006
- 2006-02-27 JP JP2007557486A patent/JP2008531647A/ja active Pending
- 2006-02-27 CA CA002598613A patent/CA2598613A1/en not_active Abandoned
- 2006-02-27 JP JP2007557485A patent/JP5714203B2/ja not_active Expired - Fee Related
- 2006-02-27 US US11/817,572 patent/US20080194506A1/en not_active Abandoned
- 2006-02-27 WO PCT/EP2006/060306 patent/WO2006094917A2/en not_active Ceased
- 2006-02-27 KR KR1020077023861A patent/KR20070121001A/ko not_active Withdrawn
- 2006-02-27 EP EP06708536A patent/EP1853277A1/en not_active Ceased
- 2006-02-27 AU AU2006222044A patent/AU2006222044A1/en not_active Abandoned
- 2006-02-27 KR KR1020077021114A patent/KR20070120954A/ko not_active Withdrawn
- 2006-02-27 US US11/817,575 patent/US20080194507A1/en not_active Abandoned
- 2006-02-27 AU AU2006222045A patent/AU2006222045B2/en not_active Ceased
- 2006-02-27 MX MX2007010754A patent/MX2007010754A/es not_active Application Discontinuation
- 2006-02-27 EP EP06708537A patent/EP1855697A2/en not_active Withdrawn
- 2006-02-27 WO PCT/EP2006/060304 patent/WO2006094916A1/en not_active Ceased
- 2006-02-27 KR KR1020077021110A patent/KR20070120953A/ko not_active Withdrawn
- 2006-02-27 MX MX2007010407A patent/MX2007010407A/es not_active Application Discontinuation
- 2006-02-27 CA CA2598072A patent/CA2598072C/en not_active Expired - Fee Related
-
2007
- 2007-08-09 IL IL185182A patent/IL185182A0/en active IP Right Grant
- 2007-08-09 IL IL185181A patent/IL185181A0/en unknown
- 2007-08-14 IL IL185258A patent/IL185258A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2598072A1 (en) | 2006-09-14 |
| US20080194506A1 (en) | 2008-08-14 |
| AU2006222044A1 (en) | 2006-09-14 |
| EP1855697A2 (en) | 2007-11-21 |
| AU2006222045A1 (en) | 2006-09-14 |
| JP2008531647A (ja) | 2008-08-14 |
| JP2008531646A (ja) | 2008-08-14 |
| IL185258A0 (en) | 2008-02-09 |
| WO2006094917A3 (en) | 2006-12-14 |
| EP1853277A1 (en) | 2007-11-14 |
| KR20070120953A (ko) | 2007-12-26 |
| US20080194507A1 (en) | 2008-08-14 |
| JP5714203B2 (ja) | 2015-05-07 |
| CA2598613A1 (en) | 2006-09-14 |
| WO2006094916A1 (en) | 2006-09-14 |
| IL185258A (en) | 2010-12-30 |
| WO2006094917A2 (en) | 2006-09-14 |
| WO2006094917A8 (en) | 2008-01-31 |
| IL185181A0 (en) | 2008-01-20 |
| KR20070121001A (ko) | 2007-12-26 |
| MX2007010754A (es) | 2007-11-07 |
| MX2007010407A (es) | 2007-10-17 |
| KR20070120954A (ko) | 2007-12-26 |
| AU2006222045B2 (en) | 2011-10-20 |
| CA2598072C (en) | 2016-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL185182A0 (en) | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors | |
| ZA200805760B (en) | Method for treating disseminated cancer | |
| IL188430A0 (en) | Treatment of tumors | |
| ZA200708575B (en) | Methods and compositions for treating or preventing cancer | |
| ZA200804238B (en) | Agents for treating cardiopathy | |
| EP1961065A4 (en) | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| ZA200800006B (en) | Composition for treating skin lesions | |
| ZA200709620B (en) | Methods for treating drug resistant cancer | |
| EP2081437A4 (en) | METHODS OF TREATING OR PREVENTING INFESTATION | |
| EP1868435A4 (en) | COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| PT1830847E (pt) | Tratamento para o cancro | |
| EP1909854A4 (en) | METHOD FOR TREATING CANCER | |
| GB0514889D0 (en) | Oligonucleotides | |
| EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| EP2088862A4 (en) | METHOD OF TREATING CANCER | |
| GB0413346D0 (en) | Treating cancer | |
| EP1883405A4 (en) | METHODS OF TREATING NEPHROLITHIASIS | |
| IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
| TWI349958B (en) | Substrate treating apparatus | |
| GB0507685D0 (en) | Cancer treatment | |
| GB0710871D0 (en) | Cancer treatment | |
| GB0503566D0 (en) | Treatment for cancer | |
| HU0500612D0 (en) | Treating apparatus for preventing cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |